1. Home
  2. XBIO vs MITQ Comparison

XBIO vs MITQ Comparison

Compare XBIO & MITQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xenetic Biosciences Inc.

XBIO

Xenetic Biosciences Inc.

HOLD

Current Price

$2.40

Market Cap

6.9M

Sector

Health Care

ML Signal

HOLD

Logo Moving iMage Technologies Inc.

MITQ

Moving iMage Technologies Inc.

HOLD

Current Price

$0.63

Market Cap

6.2M

ML Signal

HOLD

Company Overview

Basic Information
Metric
XBIO
MITQ
Founded
N/A
N/A
Country
United States
United States
Employees
N/A
25
Industry
Biotechnology: Pharmaceutical Preparations
Telecommunications Equipment
Sector
Health Care
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
6.9M
6.2M
IPO Year
2011
2019

Fundamental Metrics

Financial Performance
Metric
XBIO
MITQ
Price
$2.40
$0.63
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 93.6K
86.4K
Earning Date
05-13-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 38.52
N/A
EPS
N/A
★ N/A
Revenue
$2,976,411.00
★ $20,139,000.00
Revenue This Year
$2.81
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$58.00
Revenue Growth
★ 19.04
N/A
52 Week Low
$1.90
$0.42
52 Week High
$13.93
$1.23

Technical Indicators

Market Signals
Indicator
XBIO
MITQ
Relative Strength Index (RSI) 38.27 56.39
Support Level $2.09 $0.62
Resistance Level $2.95 $0.66
Average True Range (ATR) 0.36 0.05
MACD -0.19 0.00
Stochastic Oscillator 14.89 50.53

Price Performance

Historical Comparison
XBIO
MITQ

About XBIO Xenetic Biosciences Inc.

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.

About MITQ Moving iMage Technologies Inc.

Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.

Share on Social Networks: